{
  "slug": "nearwave",
  "name": "NearWave",
  "yc_id": 25650,
  "batch": "Winter 2022",
  "website": "http://nearwave.co",
  "web_data": {
    "web_enrichment_version": "1.0.0",
    "enriched_at": "2025-10-17T01:12:45.521330",
    "website": "http://nearwave.co",
    "website_status": {
      "reachable": true,
      "status_code": 200,
      "response_time_ms": 5858.61,
      "final_url": "https://nearwave.co/",
      "redirected": true,
      "checked_at": "2025-10-17T01:12:51.379960"
    },
    "ssl_security": {
      "disabled": true,
      "reason": "certificate_verification_failed"
    },
    "domain_info": {
      "domain": "nearwave.co",
      "registrar": "Fastdomains",
      "creation_date": "2020-05-20T00:50:31",
      "expiration_date": "2026-05-20T23:59:59",
      "domain_age_days": 1976,
      "domain_age_years": 5.4,
      "name_servers": [
        "NS1.BLUEHOST.COM",
        "NS2.BLUEHOST.COM"
      ]
    },
    "social_links": {
      "twitter": "https://twitter.com/NearWave/",
      "linkedin": "https://www.linkedin.com/company/nearwave/about/",
      "github": null,
      "facebook": "https://www.facebook.com/nearwave/",
      "instagram": "https://www.instagram.com/nearwave/",
      "youtube": null
    },
    "security_headers": {
      "strict_transport_security": false,
      "content_security_policy": false,
      "x_frame_options": false,
      "x_content_type_options": false,
      "x_xss_protection": false,
      "referrer_policy": false,
      "security_score": 0,
      "server": "Apache"
    }
  },
  "enrichment_version": "1.0.0",
  "enriched_at": "2025-10-17T10:39:36.532122",
  "phase1_complete": true,
  "phase2_complete": false,
  "phase3_complete": false,
  "phase4_complete": false,
  "phase5_complete": false,
  "ai_insights": {
    "ai_insights_version": "1.0.0-claude",
    "model_used": "claude-sonnet-4-20250514",
    "enriched_at": "2025-10-17T10:55:26.106488",
    "market_analysis": {
      "market_size": "very large",
      "market_stage": "growing",
      "key_trends": [
        "Precision medicine adoption in oncology",
        "Shift toward personalized cancer treatment",
        "Growing emphasis on reducing healthcare costs through better treatment selection"
      ]
    },
    "competitive_positioning": {
      "competitive_moat": "Proprietary handheld imaging technology with potential IP protection and clinical validation data",
      "differentiation": "Point-of-care handheld device vs traditional lab-based testing for therapy selection",
      "competitive_advantages": [
        "Real-time results at point of care",
        "Potentially lower cost than genomic testing",
        "Improved patient experience with faster decisions"
      ],
      "competitive_vulnerabilities": [
        "Established genomic testing companies with proven efficacy",
        "Potential for larger medtech companies to develop competing solutions"
      ]
    },
    "business_model": {
      "revenue_model": "hardware",
      "scalability": "medium",
      "capital_intensity": "high"
    },
    "growth_assessment": {
      "growth_stage": "seed",
      "growth_indicators": [
        "Y Combinator validation",
        "5+ year domain suggests sustained development",
        "Active status indicates ongoing progress"
      ],
      "growth_bottlenecks": [
        "FDA regulatory approval timeline",
        "Clinical validation requirements",
        "Hospital adoption cycles"
      ]
    },
    "risk_analysis": {
      "market_risk": "medium",
      "technology_risk": "high",
      "execution_risk": "high",
      "overall_risk_score": 7,
      "key_risks": [
        "Regulatory approval uncertainty",
        "Clinical efficacy validation challenges",
        "Competition from established diagnostic companies"
      ]
    },
    "investment_thesis": {
      "strengths": [
        "Addresses critical unmet need in cancer care",
        "Large addressable market",
        "Potential for significant patient impact"
      ],
      "concerns": [
        "High regulatory hurdles",
        "Long development and validation timeline",
        "Capital intensive hardware model"
      ],
      "exit_potential": "acquisition",
      "comparable_companies": [
        "Guardant Health",
        "Foundation Medicine"
      ]
    },
    "recommendations": {
      "next_steps": [
        "Focus on clinical validation studies",
        "Build relationships with key opinion leaders in oncology"
      ],
      "expansion_opportunities": [
        "Expand to other cancer types beyond breast cancer",
        "International market expansion post-FDA approval"
      ]
    },
    "tokens_used": {
      "input": 670,
      "output": 563,
      "total": 1233,
      "estimated_cost": 0.010455
    },
    "status": "success"
  },
  "phase8_complete": true
}